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A B S T R A C T
The cannabinoid-1 receptor (CB1) plays a critical role in a number of biological processes including nutrient
intake, addiction and anxiety-related behaviour. Numerous studies have shown that expression of the gene
encoding CB1 (CNR1) is highly dynamic with changes in the tissue speciﬁc expression of CNR1 associated with
brain homeostasis and disease progression. However, little is known of the mechanisms regulating this dynamic
expression. To gain a better understanding of the genomic mechanisms modulating the expression of CNR1 in
health and disease we characterised the role of a highly conserved regulatory sequence (ECR1) in CNR1 intron 2
that contained a polymorphism in linkage disequilibrium with disease associated SNPs. We used CRISPR/CAS9
technology to disrupt ECR1 within the mouse genome. Disruption of ECR1 signiﬁcantly reduced CNR1 ex-
pression in the hippocampus but not in the hypothalamus. These mice also displayed an altered sex-speciﬁc
anxiety-related behavioural proﬁle (open ﬁeld test), reduced ethanol intake and a reduced hypothermic response
following CB1 agonism. However, no signiﬁcant changes in feeding patterns were detected. These data suggest
that, whilst not all of the expression of CNR1 is modulated by ECR1, this highly conserved enhancer is required
for appropriate physiological responses to a number of stimuli. The combination of comparative genomics and
CRISPR/CAS9 disruption used in our study to determine the functional eﬀects of genetic and epigenetic changes
on the activity of tissue-speciﬁc regulatory elements at the CNR1 locus represent an important ﬁrst step in
gaining a mechanistic understanding of cannabinoid regulatory pharmacogenetics.
1. Introduction
The cannabinoid-1 receptor (CB1) is extensively expressed in areas
of the nervous system, where it plays a critical role in appetite reg-
ulation (Pomorska et al., 2016), the reward system and anxiety-related
behaviour (Akirav, 2011). A number of studies have shown that ex-
pression of the gene encoding CB1 (CNR1) is highly tissue speciﬁc and
subject to dynamic regulation during embryonic development, normal
homeostasis as well as during the progression of various disease states
(Laprairie et al., 2012). Although previous work has identiﬁed the
promotor regions regulating the expression of CNR1 (Zhang et al.,
2004) very little is known of the genomic mechanisms that regulate the
dynamic tissue speciﬁc expression of this critical gene. Gaining an un-
derstanding of the mechanisms regulating CNR1 will not only lead to an
understanding of the eﬀects of regulatory polymorphisms and
epigenetics on the changing expression of CNR1 but may also allow us
to better devise personalised strategies to counter conditions such as
substance abuse and anxiety disorders.
Because the CNR1 gene and its promoter region lack common
polymorphisms that had been associated with disease we chose to study
a region of CNR1 intron 2 which contained a linkage disequilibrium
block that contained two single nucleotide polymorphisms (SNPs;
rs2023239 and rs9450898) that had previously been associated with
addictive behaviours (Ketcherside et al., 2017), depression (Icick et al.,
2015), psychosis (Suarez-Pinilla et al., 2015), reduced hippocampal
volume in cannabis abuse (Schacht et al., 2012), nicotine addiction
(Chen et al., 2008), obesity (Benzinou et al., 2008) and alcohol abuse
(Hutchison et al., 2008; Pava and Woodward, 2012). There is growing
evidence that functional enhancer regions are often highly conserved
(Montalbano et al., 2017) so we previously used a combination of
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comparative genomics, molecular biology and primary cell based stu-
dies to identify a highly conserved enhancer element in intron 2 of the
CNR1 gene that we called evolutionary conserved region 1 (ECR1)
(Nicoll et al., 2012) and which contained a SNP (rs9444584) that was in
strong linkage disequilibrium (LD) with rs2023239 and rs9450898. In
our previous study we had shown that polymorphic variants of ECR1
(ECR1T and C) supported diﬀerent levels of marker gene expression
when transfected into diﬀerent primary cell types (Nicoll et al., 2012).
However, we were unable to determine the role of this regulatory ele-
ment in either the expression of the CNR1 gene or in physiology and
behaviour. In the current study we have used CRISPR genome editing
technology to disrupt the ECR1 enhancer in mice. We then went on to
investigate the eﬀects of this deletion on CNR1 gene expression in
hippocampus and hypothalamus; two areas of the brain where ex-
pression of CB1 is important in modulating mood and appetite. We also
analysed aspects of mouse behaviour including cannabinoid response,
alcohol intake, locomoter activity and thigmotaxis; an indicator of an-
xiety-related behaviour. The signiﬁcance of these observations is dis-
cussed in the context of cannabinoid pharmacogenomics and disease.
2. Materials and methods
2.1. Generation of gRNA molecules by a novel annealed oligo template
(AOT) method
Single guide RNA (sgRNA) molecules were designed to disrupt the
mouse ECR1 enhancer (ECR1; Fig. 1) using the optimised CRISPR de-
sign tool (http://CRISPR.mit.edu/). To remove the need for cloning of
the guide RNA template into a plasmid as previously described (Harms
et al., 2014) we devised a cloning-free technique for the production of
sgRNA. This involved the annealing and PCR ampliﬁcation of two oli-
gonucleotides: the ﬁrst oligonucleotide (80mer; 5′-AAAAAAAGCACCG
ACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACT
TGCTATTTCTAGCTCTAA-3′), represented the sgRNA scaﬀold and acted
as a generic oligonucleotide for the generation of all subsequent tem-
plates; the second oligonucleotide, (63mer; 5′-TTAATACGACTCACTA
TAGGNNNNNNNNNNNNNNNNNNNGTTTTAGAGCTAGAAATAGCAAG
-3′), where “N “denotes the predicted guide sequence (5′sgRNA; ATA
GTAAAAGAACGATTGAA and 3′sgRNA; CTCTCCATGCAAAAATAAGG)
underlined sequence represents the T7 promoter and italic sequence
represents sequence complimentary to the template scaﬀold oligo,
acted as the targeted sequence to the region of interest. These oligo-
nucleotides were ampliﬁed using 30 cycles of a standard PCR reaction
(92 °C, 30 s, 60 °C; 30 s, 72 °C 30 s) to produce a 122 bp double strand
sgRNA template. 100 ng of this template was used to produce sgRNA
using a mMESSAGE mMACHINE T7 in-vitro transcription kit (Ambion)
described in the manufacturer’s instructions and puriﬁed using a
Megaclear kit (Ambion) with modiﬁcations by Harms et al (2014).
2.2. Production of transgenic and genome edited mice
RNA (10 ng/μl each gRNA as produced above) and mRNA encoding
a wild type CAS9 with a nuclear localisation signal (Life Technologies)
was microinjected into the cytoplasm (RNA) of 1-cell C57/BL6 embryos
as described (Harms et al., 2014). Surviving two-cell embryos were
introduced into host CD1 mothers using oviduct transfer as previously
described (Nagy et al., 2003). Once weaned, ear-clip biopsies were re-
covered and analysed by PCR using ECR1 ﬂanking primers (mECR1 test
for; TGTGTGCAGAGAGGGGAGAC; mECR1 test rev; CTTTAGGAGTGG
ACAAGGGGTC) as previously described (Harms et al., 2014).
2.3. Quantitative reverse transcriptase-PCR
Brain tissues (hypothalamus and hippocampus) were dissected and
snap frozen on dry ice. Total RNA was extracted using the isolate II RNA
minikit and converted to cDNA using reverse transcriptase (Bioline).
Quantitative reverse transcriptase-PCR (QrtPCR) to determine mRNA
expression levels of mouse CNR1 was undertaken using gene speciﬁc
primers (CNR1for. 5′-GGATGCGAAGGGGTTCCCTC-3′; CNR1rev.
5′-AACCAACGGGGAGTTGTCTC-3′) on derived cDNA using mouse Qrt-
PCR primers as previously described (Shanley et al., 2010, 2011) using
a Roche Light Cycler 480 with Roche SYBR green. All QrtPCR analyses
were normalised using mouse primers speciﬁc to the Nono house-
keeping gene (Nonofor. 5′-GCCAGAATGAAGGCTTGACTAT-3′; Non-
orev. 5′-TATCAGGGGGAAGATTGCCCA-3′) that gave the most stable
expression in all neuronal tissues analysed compared to the βactin,
HPRT or GAPDH genes.
2.4. Animal maintenance
All mice were housed under standard UK Home Oﬃce approved
laboratory conditions (12 h light/12 h dark cycle and constant tem-
perature (22 ± 2 °C) and humidity (55 ± 10%)), with food and water
available ad libitum.
2.5. Ethanol intake studies
Oral ethanol self-administration and preference were examined
using a two-bottle choice protocol as described previously (Hungund
et al., 2003). Mice were housed in TSE home cage systems (TSE, Bad
Homburg, Germany) that record liquid intake automatically using
weight sensors attached to suspended liquid containers. Initially mice
were group housed (˜4 per cage) and habituated for 5 days to allow for
adaptation to the monitored bottles, then they were single housed for 3
days prior to introduction of the ethanol solution. Intake of water and
10% ethanol solution (both containing 0.2% saccharine to normalise
preference to ethanol) were monitored at 60min intervals over a 3-
week period and recorded by TSE PhenoMaster Software. These mice
were not used for subsequent tests.
2.6. Hypothermic response studies
Win55,212-2 was dissolved to 1mg/ml in ethanol and mixed with
2mg/ml tween 80 in ethanol in a 1:1 ratio. Ethanol was evaporated oﬀ
and the drug/tween 80 mixture was reconstituted in 0.9% saline.
Homozygous wildtype and ECR1KO mice male and female age matched
littermates (6–12 weeks old) were injected i.p. with 5mg/kg of
Win55,212-2 and core temperature measurements taken at 0min,
30min and 60min using a rectal thermometer inserted 2 cm (Rawls
et al., 2002). These mice were not used for subsequent tests.
2.7. Food intake analysis
For food intake studies, singly housed male and females litter and
age matched (12–20 weeks) ECR1KO and WT animals were provided
with a choice of low fat diet (LFD) or high fat diet (HFD) (LFD;
22.03 kcal% protein, 68.9 kcal% carbohydrate and 9.08 kcal% fat. HFD;
20 kcal% protein, 20 kcal% carbohydrate and 60 kcal % fat; Research
Diets Inc.) in diﬀerent hoppers. The position of each hopper was
changed regularly to rule out the possibility of position eﬀects. Animals
were weighed daily over a period of 23 days and LFD and HFD were
also weighed daily to determine intake of each diet. These mice were
not used for subsequent tests
2.8. Body fat mass composition
Body fat mass versus lean mass composition of each mouse in
feeding studies was analysed at the beginning of the food intake study
and at the end using an Echo MRI-3-in-1 scanner (Echo Medical
Systems, Houston, TX, USA). Mice were placed individually into a
plastic tube and inserted into the scanner where total body fat and lean
mass were determined at the beginning and at the end of each study.
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2.9. Open Field test
Movement and thigmotaxis in ECR1 deletion and WT littermate
male and female age matched (6–12weeks) mice was tested using the
open ﬁeld test (Crawley, 1985). Brieﬂy, the open ﬁeld test consisted of a
square 30 cm (30 cm high) PVC open ﬁeld arena positioned on a white
base with overhead lighting applying 100 lx at the base. Animals were
transported individually to the testing room, habituated (30min.) and
released into the corner of the arena. Ambulatory activity was recorded
in the open ﬁeld for 600 s using an overhead video camera and the
ANY-maze tracking software. The software was used to deﬁne a 35 cm2
mid zone and 30 cm2 peripheral zone. Travel between these zones was
referred to as “line crossings”. Distance travelled, mean speed, time in
peripheral zone, entries into centre zone and time in centre zone, were
determined by the software. Many of these mice were included in
subsequent food intake studies.
2.10. Data analysis
Statistical signiﬁcance of data sets was analysed using two-tailed
unpaired parametric Student t-test using GraphPad PRISM version 5.02
(GraphPad Software, La Jolla, CA, USA) except for data in Fig. 4D
which was analysed using 2-way ANOVA. p-values, numbers used, and
t-values are displayed for each graph in the ﬁgure legends for sig-
niﬁcant. ANOVA analysis for Fig. 4D includes the p-value and F-value.
2.11. Ethics
All animal experiments were conducted in full accordance with UK
Home Oﬃce guidelines as stipulated in the Animals in Scientiﬁc
Fig. 1. Bioinformatic analysis of the human CNR1 locus using the UCSC genome browser. A. Genetic linkage analysis within intron 2 of the human CNR1 locus
showing degrees of linkage disequilibrium between disease associated SNPs (rs2023239 and rs9450898; highlighted by red boxes) and rs9444584 (Green box). Deep
red triangles indicate linkage disequilibrium expressed as r2> 0.95 and pink r2> 0.9. B. Sequence analysis of the mouse ECR1 enhancer region showing levels of
mammalian conservation (blue peaks) and depth of conservation (green bars). Long black bars labelled with numbers (41,39,32,36,28,29,38,31,30,37) reﬂect the
alignment of sequences derived from PCR products ampliﬁed from ear plug DNA of CRISPR genome edited mice. Deletions are indicated by thin lines covered in
chevrons. Short black bars (gRNAECR1a and gRNAECR1b) reﬂect the regions targeted by the guide RNA used to target the ECR1 locus. The red line highlights where
the rs9444584 polymorphisms within the ECR1 enhancer lies within the equivalent human locus. (For interpretation of the references to colour in this ﬁgure legend,
the reader is referred to the web version of this article).
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Research act of 1986. This study was undertaken under a current UK
Home Oﬃce 5-year project licence (PPL number: P5D8BAA7D) which
was subjected to ethical review by the University of Aberdeen ethical
review board prior to submission to the Home Oﬃce in 2016. Animals
were euthanised using UK Home Oﬃce approved schedule-1 techni-
ques.
3. Results
Our previous studies used a combination of comparative genomics
and linkage disequilibrium analysis to identify a highly conserved
polymorphic sequence (ECR1; rs9444584) within intron 2 of the CNR1
gene that was in strong LD with two other SNPs (Fig. 1A, rs2023239
and rs9450898) that were previously associated with various patholo-
gies (Benzinou et al., 2008; Chen et al., 2008; Hutchison et al., 2008;
Icick et al., 2015; Ketcherside et al., 2017; Pava and Woodward, 2012;
Schacht et al., 2012; Suarez-Pinilla et al., 2015) and which displayed
allele speciﬁc diﬀerential enhancer activity in diﬀerent tissues (Nicoll
et al., 2012). In the current study we asked whether this enhancer could
be disrupted using CRISPR genome editing and what eﬀects disrupting
this enhancer would have on the expression of the endogenous CNR1
gene in diﬀerent tissues as well as a broad analysis of food and alcohol
intake, cannabinoid response, movement and anxiety-related beha-
viour.
3.1. Cytoplasmic microinjection of gRNA; produced using the AOL protocol,
and Cas9 mRNA eﬃciently disrupts the ECR1 enhancer in mice
All animal experiments complied with current U.K. Home Oﬃce
Animals (Scientiﬁc Procedures) Act (1986) guidelines. To determine the
possible function of the ECR1 sequence we used CRISPR genome editing
to disrupt the most highly conserved core region of ECR1 from the
mouse genome (Fig. 1A). This was done by microinjecting guide RNA
molecules (gRNA; gRNAECR1a and gRNAECR1b; Fig. 1B), produced
using our AOL method (see materials and methods), and designed to
disrupt the core region of ECR1, centred on a sequence homologous to
that containing the human rs9444584 polymorphism (Fig. 1B), together
with CAS9 mRNA into the cytoplasm of fertilised single cell mouse
embryos. We injected 120 1-cell embryos with gRNA and Cas9 mRNA
and transferred 90 surviving 2 cell embryos into 4 pseudopregnant fe-
male mice. These mice gave birth to 23 pups of which 10 proved to be
homozygous for the ECR1 disruption (Fig. 2A). Sequence analysis of
earclip DNA demonstrated that 90% of deletions were within +/- 20
base pairs of the PAM sequences associated with each gRNA (Fig. 1B).
We derived 3 lines containing nearly identical deletions of ECR1
(Fig. 1B; ECR1KO lines 29, 30 and 31) that closely matched the PAM
sequence of our guides. Further analysis of earclip DNA explored the
top 5 likely oﬀ target sequences (Sequences within the mouse genome
that diﬀered by one or two base pairs) from the founder line but could
not identify any evidence of oﬀ-target changes to the genomes of any of
the lines chosen for further analysis (Hay et al., 2016).
3.2. Disruption of the CR1 sequence reduced the expression of CNR1 in
hippocampal cells but not the hypothalamus
To determine the eﬀects of disrupting ECR1 in mice we used QrtPCR
to detect tissue changes in the expression of CNR1 mRNA in tissues
derived from the hippocampus and the hypothalamus of ECR1KO and
age and sex matched wild type littermates. ECR1KO animals had a 17%
reduction in CNR1 mRNA in the hippocampus (Fig. 2A) but not in the
hypothalamus (Fig. 2B). These observations suggest a role for ECR1 as a
tissue speciﬁc regulatory sequence with greater relevance for CNR1
expression in the hippocampus.
3.3. Disruption of ECR1 reduces the CB1 activated hypothermic response
Mice lacking CB1 have a reduced hypothermic response to CB1
agonists (Ledent et al., 1999). In order to assess the eﬀects of ECR1
deletion of CB1 activity we tested the well-known hypothermic re-
sponse of wild type and ECR1KO animals treated with the CB1 agonist
Win55,212-2(Grim et al., 2016). We injected adult male and female
ECR1KO and wild-type mice with the CB1 agonist Win55,212-2 (5mg/
kg; i.p) (Irving et al., 2000). We were unable to detect any sex speciﬁc
diﬀerence in Win55,212-2 response (data not shown) but we observed
that, 30min after injection, ECR1KO mice of both sexes displayed a
signiﬁcantly reduced hypothermic response compared to wild types
(WT) consistent with a change in CB1 receptor expression (Fig. 3A). The
diﬀerence in eﬀect between ECR1KO and WT animals, although still
observable, became non-signiﬁcant at 60min after injection (Fig. 3B).
3.4. Disruption of ECR1 did not aﬀect food intake or weight gain
Previous analysis had shown that deletion of the CNR1 gene (Cota
et al., 2003) or treatment of mice with CB1 antagonists (Viveros et al.,
2008) signiﬁcantly decreased food intake and fat deposition in mice. To
determine whether ECR1 played a role in food intake or fat deposition
we provided age matched ECR1KO and WT male and female littermate
mice (12–18 weeks old) with free access to two hoppers containing high
fat diet (HFD; 60% of calories from fat) or low-fat diet (4% of calories
from fat). No signiﬁcant change in preference for HFD over LFD was
detected (data not shown). Furthermore, no signiﬁcant change in
overall food intake was observed because of ECR1 deletion after 29
days exposure to ad libitum HFD/LFD exposure (Fig. 3C). To detect
possible changes in fat/lean mass each animal was assessed using echo
MRI scanning at the beginning of the trial and at the end (29 days) and
no signiﬁcant diﬀerence was observed in the deposition of fat between
Fig. 2. Bar graphs showing QrtPCR analysis of
mouse CNR1 expression in total RNA derived
from A, hippocampus (p=0.0182, t= 2.142)
and B, hypothalamus (p= 0.8132, t= 0.2379)
comparing CNR1 mRNA expression in wild
type (WT) and ECR1KO (KO) animals normal-
ised to the Nono reference gene (n= 19–31;
error bars= SDM, *=p<0.05, ns= not sig-
niﬁcant).
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these groups of animals (Fig. 3D) suggesting that ECR1 did not play an
important role in appetite or weight gain.
3.5. Disruption of ECR1 reduced alcohol intake in mice
Mice lacking the CB1 gene have reduced ethanol intake (Hungund
et al., 2003) and pharmacological blockade of CB1 also has an eﬀect on
alcohol intake (Femenia et al., 2010; Lallemand and De Witte, 2006)
demonstrating an important mechanistic link between CB1 expression
and alcohol consumption. We therefore explored the eﬀects of the ECR1
knockout on the ethanol intake of ECR1KO mice in comparison to wild
type littermates by exposing singly housed ECR1KO and WT mice to a
choice of either water or water and 10% ethanol. We observed that,
despite having the same total ﬂuid intake (Fig. 4A), ECR1KO mice
drank signiﬁcantly less 10% ethanol than WT animals (Fig. 4B and C)
over the 16 days that they were exposed to the choice. Overall ECR1KO
animals drank less than half of the 10% ethanol drunk by their wild
type littermates.
3.6. Disruption of the ECR1 enhancer aﬀected thigmotaxis in a sex speciﬁc
manner but not locomotor activity
Previous studies of CNR1 knockout animals have indicated a com-
plex role for CB1 in modulating anxiety-related behaviour (Patel and
Hillard, 2009). CB1 expression in the hippocampus plays a role in an-
xiety-related behaviour (Bambico et al., 2009; Viveros et al., 2007) and
we demonstrate that disruption of the ECR1 enhancer reduced expres-
sion of CNR1 mRNA in the hippocampus by 17%. To determine whether
disruption of ECR1 inﬂuenced levels locomotor activity or anxiety-re-
lated behaviour we compared the behaviour of male and female wild
Fig. 3. A and B Comparison of core tempera-
ture measurements from wild type (WT) and
ECR1KO (KO) animals taken (A) 30min
(p= 0.04, t= 2.131) and (B) 60min (t-test,
p= 0.09, t= 1.744) after intraperitoneal (i.p.)
injection of 5mg/kg of Win55,212-2
(n= 17–19; error bars= SDM). C
Comparisons of total food intake (g) in
ECR1KO (KO) and wild type (WT) animals al-
lowed ad libitum access to a choice of low fat
and high fat diet over 29 days (n= 8;
p=0.17, t= 1.419). D. Comparisons of fat
mass deposition in ECR1KO (KO) and wild type
(WT) animals assessed using Echo-MRI scan-
ning before and after 29 days of ad libitum ac-
cess to a choice of low fat and high fat diet
(n= 8; ns= no signiﬁcance, 2-way ANOVA,
p=0.48, F= 0.85).
Fig. 4. A Comparison of total ﬂuid intake over 400 h by wild type (WT) and ECR1KO animals given a choice of drinking water or water and 10% ethanol (n= 11–16;
error bars= SDM, ns=no signiﬁcance, p= 0.33, t= 1.008). B, a time plot comparing cumulative hourly intake of 10% ethanol between WT (grey triangles) and
ECR1KO (black squares) age matched littermates over a 400 -h period (n= 11–16; error bars= SDM). C, a comparison of total intake of 10% ethanol expressed as a
percentage of total intake comparing wild type and ECR1KO animals over the 400 h of the study (n= 11–16; error bars= SDM, p=0.02, t= 2.454).
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type and ECR1KO animals using the open ﬁeld test (OFT); an accepted
model of locomotor activity, and thigmotaxis; an anxiety-related be-
haviour that increases the need for an animal to make contact with a
solid object such as a wall, in mice (Crawley, 1985) (Seibenhener and
Wooten, 2015). We were unable to detect any signiﬁcant diﬀerence in
the speed or distance travelled by male or female ECR1KO and WT
littermates within the arena of the OFT suggesting that disruption of
ECR1 had no eﬀect on male or female locomotor activity (Fig. 5A and
B). However, we observed increased thigmotaxis in female ECR1KO
mice; reﬂected by their need to stay at the periphery of the arena,
compared to wild type mice, and a corresponding reduction in centre
entries and time spent there (Fig. 5C–E). In contrast, ECR1 KO mice
displayed signiﬁcantly reduced thigmotaxis and a corresponding in-
crease in centre entries and time spent there (Fig. 5 C–E). Interestingly,
male wild type mice deposited more fecal boli than male ECR1KO mice
(Fig. 5F) which also represents an accepted measure of anxiety-related
behaviour in mice (Crawley, 1985). Although more tests are required to
make a certain conclusion regarding the anxiety status of these animals
the changes in thigmotaxis and centre entry times displayed by our
ECR1KO male and female animals suggest that ECR1 may play a role in
modulating anxiety-related behaviour in mice.
4. Discussion
We had previously demonstrated the presence of a highly conserved
and polymorphic region of DNA within intron 2 of the CNR1 gene that
demonstrated an ability to upregulate promoter function in diﬀerent
primary neuronal cell types (Nicoll et al., 2012). In addition, diﬀerent
polymorphic variants of ECR1 induced altered levels of TATA box
promoter activity suggesting that polymorphic variation within ECR1
may play a functional role in determining the activity of the CNR1
promoter (Zhang et al., 2004). Following our discovery that ECR1 had
enhancer-like properties we asked whether ECR1 played a role in
modulating CNR1 gene expression in vivo. We also asked whether
disrupting ECR1 would have any eﬀects on physiologies associated with
changes in CB1 expression including cannabinoid response, food and
alcohol intake, movement or anxiety-related behaviour.
Analysis of tissues derived from animals containing the CAS9-driven
ECR1 disruption demonstrated a signiﬁcant reduction of CNR1 mRNA
within the hippocampus of these animals compared to wild type lit-
termates but did not seem to aﬀect gross levels of CNR1 mRNA ex-
pression in the hypothalamus. These observations suggest that the
mouse ECR1 enhancer; that is represented by the ancestral T-allele in
all mammalian species except humans, has tissue speciﬁc properties
and is only required to support the expression of the CNR1 gene in
speciﬁc tissues and at speciﬁc times. The observation that ECR1 only
supports CNR1 mRNA expression in the hippocampus is not surprising
as many genes depend on the combined input of many enhancers to
ensure that they are expressed in appropriate levels in diﬀerent cell
types and in response to the correct cues (Rickels and Shilatifard,
2018). Moreover, expression of CNR1 and CB1 in hippocampus has
been previously shown to be markedly diﬀerent to that found in the
hypothalamus providing further evidence of the existence of diﬀerent
regulatory mechanisms governing CNR1 expression in these regions
(Howlett et al., 2002). Although we have identiﬁed a reduction in gross
CNR1 expression in our ECR1KO mice, more localised comparisons of
CNR1 mRNA expression remains to be done in more localised regions of
the brain such as the nucleus accumbens, amygdala, ventral tegmental
area and pre-frontal cortex.
The observation that disruption of ECR1 reduces the hypothermic
response of CB1 agonism was consistent with a role for ECR1 in con-
trolling CB1 receptor expression. The modulation of body temperature
by CB1 agonism is regulated by a part of the hypothalamus known as
the preoptic anterior hypothalamus (POAH) (Rawls et al., 2002).
However, as described above, we were unable to detect any change in
the expression of the CNR1 mRNA in hypothalamic tissues by QrtPCR.
This suggests that ECR1 only controls CNR1 expression in a small re-
gion of the hypothalamus and, judging by the eﬀects of ECR1 disruption
on thermoregulation following CB1 agonism, within groups of cells that
include the POAH. Fine dissection of the POAH followed by QrtPCR
Fig. 5. An open ﬁeld test analysis comparing wild type (WT) and ECR1KO (KO) female and male mice demonstrating the total distance travelled (A), the average
speed of the animals (B), the time in the periphery (C), The number of entries into the centre of the test arena (D) the time spent in the centre zone of the arena (E)
and numbers of faecal boli deposited (F). n= 8–10, error bars= SDM, ns=not signiﬁcant, *; p≤ 0.05, **; p≤ 0.01. (F-values; A, p= 0.2, F=1.524; B, p= 0.3,
F=1.099; C, p= 0.0001, f= 9.647, D, p= 0.0048, F=5.082; E, p= 0.0001, F= 9.092).
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would conclusively address this hypothesis.
We also demonstrated that disruption of ECR1 reduces alcohol in-
take in both male and female mice. This observation is consistent with a
role for ECR1 in controlling CNR1 expression as mice lacking the CB1
gene have reduced ethanol intake (Hungund et al., 2003). Critically,
humans containing speciﬁc haplotypes of an LD block containing the
ECR1 enhancer are more susceptible to addictive behaviours including
addiction to alcohol (Hutchison et al., 2008). Thus, the identiﬁcation of
a polymorphic enhancer within the CNR1 locus that modulates ethanol
intake is important to our understanding of how polymorphisms within
the human genome contribute to increased alcohol intake. Previous
analyses of the regions of the brain where CB1 is known to aﬀect al-
cohol intake suggest the involvement of CB1 expression in the nucleus
accumbens (NAc) (Hungund and Basavarajappa, 2004). Future studies
will involve a more focussed analysis of CNR1 mRNA from the NAc to
determine whether the reduction in alcohol intake observed was linked
to a reduction in the expression of CNR1 mRNA in this region of the
brain. In contrast to our observed decrease in ethanol intake we did not
observe any diﬀerence in food intake or fat deposition between
ECR1KO or WT animals suggesting that the role played by ECR1 in fat
and ethanol intake diﬀered and provides clues suggesting that the
mechanisms modulating expression of the CB1 receptor in ethanol and
food intake also diﬀer.
We showed that disruption of ECR1 caused a signiﬁcant decrease in
the expression of CNR1 in the hippocampus where CB1 gene expression
plays a critical role in protecting the nervous system against the de-
pression associated eﬀects of stress (Scarante et al., 2017). We therefore
explored the eﬀects of the disruption of ECR1 on levels of anxiety-re-
lated behaviour in ECR1KO mice using the open ﬁeld test which as-
sesses locomoter movement and thigmotaxis; the need to stay close to
the walls of the test arena. The value of using thigmotaxis as a measure
of anxiety like behaviour was demonstrated when animals given an-
xiolytic drugs such as diazepan or chlordiazepoxide displayed sig-
niﬁcantly reduced thigmotaxis (Choleris et al., 2001). Female mice
displayed increased levels of thigmotaxis and spent less time in the
centre of the OFT arena suggesting increased anxiety levels in female
mice lacking ECR1 which is consistent with previous observations of
increased anxiety-related behaviour in CNR1 gene disrupted mice
(Patel and Hillard, 2009). However, in male mice we show that dis-
ruption of ECR1 appears to decrease anxiety related behaviours as these
mice spend a signiﬁcantly longer time in the centre of the OFT and less
time at the periphery. Although this observation is compelling and
consistent with a role for ECR1 in governing the manifestation of an-
xiety-related behaviour, more work needs to be done using tests such as
the elevated zero maze, light-dark experiments or novelty suppressed
feeding test before a conclusive role for ECR1 in mood modulation can
be asserted. These observations also suggest that the role of ECR1 in
anxiety-related behaviour modulation is sex speciﬁc. Whilst a great deal
of work remains to be undertaken to determine the mechanisms gov-
erning ECR1 activity with respect to the generation of anxiety-related
behaviour it is likely that the direct or indirect eﬀects of testosterone or
oestrogens on ECR1 activity, or the CNR1 promoter, would be a good
place to start.
Another possibility that requires further exploration is that ECR1
may play a dual role in modulating the tissue speciﬁc expression at the
transcriptional level whilst also modulating the identity and amount of
diﬀerent splice forms that are produced from the human CNR1 gene in
diﬀerent tissues. Fine dissection of neuronal tissues in mice lacking
ECR1 combined with mRNA isoform mRNA analysis using splice-form
speciﬁc PCR primers would allow us to address this possibility.
As mentioned above, it is likely that ECR1 only represents a small
component of the regulatory machinery required to modulate the dy-
namic expression of the CNR1 gene in the brain. Although we initially
chose to explore ECR1, due to the disease association of its SNP, we also
observed that the CNR1 locus is bracketed by many other regions of
even higher non-coding conservation, many of which have been as
highly conserved as the CNR1 coding region, that may also represent
enhancers involved in modulating CNR1 expression. Therefore, our
analysis of the ECR1 enhancer only represents the start of a larger study
to identify the core enhancer elements that modulate the expression of
the CNR1 locus.
5. Conclusions
We have used comparative genomics and CRISPR/CAS9 genome
editing to demonstrate that the ECR1 enhancer sequence plays a role in
several physiologies including anxiety-related behaviour, alcohol intake
and cannabinoid response. Moreover, we demonstrate that disruption
of ECR1 has a signiﬁcant eﬀect on the expression of the CNR1 gene in
the hippocampus. The functional analysis of the ECR1 enhancer se-
quence using the combination of comparative genomics and CRISPR
genome editing described in the current manuscript lays the foundation
for further studies on the eﬀects of polymorphic variation on the ac-
tivity of ECR1 and how these polymorphisms may contribute to an-
xiety-related disorders, substance abuse disorders. Furthermore, estab-
lishing a functional role for ECR1 in cannabinoid response may provide
a platform for exploring a role for ECR1 polymorphisms in stratiﬁed
response to drugs targeted against the CB1 receptor and in contributing
to our understanding of cannabinoid pharmacogenetics. The exciting
combination of comparative genomics and CRISPR genome editing
described in the current manuscript is a blueprint for further studies to
identify and characterise the functional non-coding elements essential
for health well as permitting novel insights into identifying the genetic
and epigenetic mechanisms contributing to disease susceptibility.
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